Brain Advance Access originally published online on June 4, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Brain, Vol. 127, No. 7, 1463-1478,
July 2004
© 2004 Guarantors of Brain
doi: 10.1093/brain/awh176
Development of biomarkers in multiple sclerosis
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
Correspondence to: Dr Bibiana Bielekova, Neuroimmunology Branch, NINDS, National Institutes of Health, Bldg. 10, Room 5B-16, 10 Center DR MSC 1400, Bethesda, MD 20892-1400, USA. E-mail: bielekob{at}ninds.nih.gov
Multiple sclerosis is a complex disease, as several pathophysiological processes (including inflammation, demyelination, axonal damage and repair mechanisms) participate in the disease process. Furthermore, as new pathological evidence reveals, these processes are not uniformly represented across patient populations but can selectively predominate in individual patients, thus contributing to the heterogeneity in phenotypic expression of the disease, its prognosis and response to therapies. While the armamentarium of available therapies for multiple sclerosis broadens, little is known about factors that predict treatment response in individual patients to a specific drug. More importantly, we are beginning to understand that, analogous to cancer therapy, the successful therapeutic strategy in multiple sclerosis might ultimately involve the combination of different therapeutics targeting several dominant pathophysiological processes. The development of these process-specific therapies will be impossible without the use of biomarkers that reflect the targeted process, can select patient population in which the targeted process is prevailing and can aid during the more rapid screening of therapeutic agents in the early phase of their development. This review summarizes the general concepts of biomarkers and their potential use as surrogate endpoints and tailors these concepts to specific applications in multiple sclerosis research.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T Mondria, C H J Lamers, P A W t. Boekhorst, J W Gratama, and R Q Hintzen Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, September 1, 2008; 79(9): 1013 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Toledo, J Sepulcre, A Salinas-Alaman, A Garcia-Layana, M Murie-Fernandez, B Bejarano, and P Villoslada Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis Multiple Sclerosis, August 1, 2008; 14(7): 906 - 912. [Abstract] [PDF]
|
|
|
|
|
|
L Durelli, P Barbero, M Bergui, E Versino, M A Bassano, E Verdun, C Rivoiro, C Ferrero, E Picco, P Ripellino, et al. MRI activity and neutralising antibody as predictors of response to interferon {beta} treatment in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, June 1, 2008; 79(6): 646 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Sadovnick and D. H. Jacobs MS and cognition and APOE: The ongoing conundrum about biomarkers Neurology, January 15, 2008; 70(3): 164 - 165. [Full Text] [PDF]
|
|
|
|
|
|
G. F. Wu, E. D. Schwartz, T. Lei, A. Souza, S. Mishra, D. A. Jacobs, C. E. Markowitz, S. L. Galetta, M. L. Nano-Schiavi, L. M. Desiderio, et al. Relation of vision to global and regional brain MRI in multiple sclerosis Neurology, December 4, 2007; 69(23): 2128 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Lehmensiek, S. Sussmuth, G. Tauscher, J. Brettschneider, S. Felk, F. Gillardon, and H. Tumani Cerebrospinal fluid proteome profile in multiple sclerosis Multiple Sclerosis, August 1, 2007; 13(7): 840 - 849. [Abstract] [PDF]
|
|
|
|
|
|
M. Ukkonen, X. Wu, B. Reipert, P. Dastidar, and I. Elovaara Cell surface adhesion molecules and cytokine profiles in primary progressive multiple sclerosis Multiple Sclerosis, July 1, 2007; 13(6): 701 - 707. [Abstract] [PDF]
|
|
|
|
|
|
J. Sepulcre, M. Murie-Fernandez, A. Salinas-Alaman, A. Garcia-Layana, B. Bejarano, and P. Villoslada Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS Neurology, May 1, 2007; 68(18): 1488 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Aranami, S. Miyake, and T. Yamamura Differential Expression of CD11c by Peripheral Blood NK Cells Reflects Temporal Activity of Multiple Sclerosis J. Immunol., October 15, 2006; 177(8): 5659 - 5667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gold and R. Hohlfeld Multiple sclerosis therapy: new agents carry new risks Practical Neurology, August 1, 2006; 6(4): 248 - 251. [Full Text] [PDF]
|
|
|
|
|
|
E Fainardi, M Castellazzi, T Bellini, M C Manfrinato, E Baldi, I Casetta, E Paolino, E Granieri, and F Dallocchio Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis Multiple Sclerosis, June 1, 2006; 12(3): 294 - 301. [Abstract] [PDF]
|
|
|
|
|
|
E Fainardi, R Rizzo, L Melchiorri, M Castellazzi, E Paolino, M R Tola, E Granieri, and O R Baricordi Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis Multiple Sclerosis, February 1, 2006; 12(1): 2 - 12. [Abstract] [PDF]
|
|
|
|
|
|
F Sellebjerg, C Ross, N Koch-Henriksen, P S. Sorensen, J L Frederiksen, K Bendtzen, and T L Sorensen CD26+CD4+T cell counts and attack risk in interferon-treated multiple sclerosis Multiple Sclerosis, December 1, 2005; 11(6): 641 - 645. [Abstract] [PDF]
|
|
|
|
|
|
B. Bielekova, N. Kadom, E. Fisher, N. Jeffries, J. Ohayon, N. Richert, T. Howard, C. N. Bash, J. A. Frank, L. Stone, et al. MRI as a marker for disease heterogeneity in multiple sclerosis Neurology, October 11, 2005; 65(7): 1071 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sastre-Garriga, G. T. Ingle, M. Rovaris, N. Tellez, B. Jasperse, D. R. Altmann, B. Benedetti, V. L. Stevenson, M. Cercignani, S. M. Leary, et al. Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data Neurology, August 23, 2005; 65(4): 633 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Lolli, B. Mulinacci, A. Carotenuto, B. Bonetti, G. Sabatino, B. Mazzanti, A. M. D'Ursi, E. Novellino, M. Pazzagli, L. Lovato, et al. An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis PNAS, July 19, 2005; 102(29): 10273 - 10278. [Abstract] [Full Text] [PDF]
|
|